Proliferation Marker Ki-67 in Early Breast Cancer
Molecular markers have been extensively investigated with a view to providing early and accurate information on long-term outcome and prediction of response to treatment of early breast cancer. Proliferation is a key feature of the progression of tumors and is now widely estimated by the immunohisto...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical oncology 2005-10, Vol.23 (28), p.7212-7220 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 7220 |
|---|---|
| container_issue | 28 |
| container_start_page | 7212 |
| container_title | Journal of clinical oncology |
| container_volume | 23 |
| creator | URRUTICOECHEA, Ander SMITH, Ian E DOWSETT, Mitch |
| description | Molecular markers have been extensively investigated with a view to providing early and accurate information on long-term outcome and prediction of response to treatment of early breast cancer. Proliferation is a key feature of the progression of tumors and is now widely estimated by the immunohistochemical assessment of the nuclear antigen Ki-67. The expression of Ki-67 correlates with other measurements of proliferation, including S-phase and bromodeoxyuridine uptake. High Ki-67 is a sign of poor prognosis associated with a good chance of clinical response to chemotherapy, but its independent significance is modest and does not merit measurements in most routine clinical scenarios. However, its application as a pharmacodynamic intermediate marker of the effectiveness of medical therapy holds great promise for rapid evaluation of new drugs. |
| doi_str_mv | 10.1200/JCO.2005.07.501 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68636864</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68636864</sourcerecordid><originalsourceid>FETCH-LOGICAL-c469t-83f8076d8129a9bba3584bcdef17bd83191085f36e2f41fe6d139fa64c55ffd13</originalsourceid><addsrcrecordid>eNpFkE1LAzEQhoMotlbP3mQv6mm3mWTzsUct9bNSDwreQnY3sanbbk1apP_elC70MLwMPPPCPAhdAs6AYDx8GU2zmCzDImMYjlAfGBGpEIwdoz4WlKQg6VcPnYUwxxhySdkp6gGHgnDM-gjefds4a7xeu3aZvGn_Y3zy6lIuErdMxto32-TeGx3WyUgvK-PP0YnVTTAXXQ7Q58P4Y_SUTqaPz6O7SVrlvFinklqJBa8lkEIXZakpk3lZ1caCKGtJoQAsmaXcEJuDNbwGWljN84oxa-MyQDf73pVvfzcmrNXChco0jV6adhMUl5zGySM43IOVb0PwxqqVdwvttwqw2llS0ZLaWVJYqGgpXlx11ZtyYeoD32mJwHUH6FDpxvr4uQsHThBKJNsV3e65mfue_TlvVFjopom1RM2rllBFpBIECP0HUH96eQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68636864</pqid></control><display><type>article</type><title>Proliferation Marker Ki-67 in Early Breast Cancer</title><source>MEDLINE</source><source>American Society of Clinical Oncology Online Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>URRUTICOECHEA, Ander ; SMITH, Ian E ; DOWSETT, Mitch</creator><creatorcontrib>URRUTICOECHEA, Ander ; SMITH, Ian E ; DOWSETT, Mitch</creatorcontrib><description>Molecular markers have been extensively investigated with a view to providing early and accurate information on long-term outcome and prediction of response to treatment of early breast cancer. Proliferation is a key feature of the progression of tumors and is now widely estimated by the immunohistochemical assessment of the nuclear antigen Ki-67. The expression of Ki-67 correlates with other measurements of proliferation, including S-phase and bromodeoxyuridine uptake. High Ki-67 is a sign of poor prognosis associated with a good chance of clinical response to chemotherapy, but its independent significance is modest and does not merit measurements in most routine clinical scenarios. However, its application as a pharmacodynamic intermediate marker of the effectiveness of medical therapy holds great promise for rapid evaluation of new drugs.</description><identifier>ISSN: 0732-183X</identifier><identifier>EISSN: 1527-7755</identifier><identifier>DOI: 10.1200/JCO.2005.07.501</identifier><identifier>PMID: 16192605</identifier><language>eng</language><publisher>Baltimore, MD: American Society of Clinical Oncology</publisher><subject>Antineoplastic Agents - pharmacokinetics ; Biological and medical sciences ; Biomarkers, Tumor - analysis ; Breast Neoplasms - drug therapy ; Breast Neoplasms - pathology ; Cell Proliferation ; Female ; Gene Expression Profiling ; Gynecology. Andrology. Obstetrics ; Humans ; Immunohistochemistry ; Ki-67 Antigen - analysis ; Mammary gland diseases ; Medical sciences ; Prognosis ; Tumors</subject><ispartof>Journal of clinical oncology, 2005-10, Vol.23 (28), p.7212-7220</ispartof><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c469t-83f8076d8129a9bba3584bcdef17bd83191085f36e2f41fe6d139fa64c55ffd13</citedby><cites>FETCH-LOGICAL-c469t-83f8076d8129a9bba3584bcdef17bd83191085f36e2f41fe6d139fa64c55ffd13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3728,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17232851$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16192605$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>URRUTICOECHEA, Ander</creatorcontrib><creatorcontrib>SMITH, Ian E</creatorcontrib><creatorcontrib>DOWSETT, Mitch</creatorcontrib><title>Proliferation Marker Ki-67 in Early Breast Cancer</title><title>Journal of clinical oncology</title><addtitle>J Clin Oncol</addtitle><description>Molecular markers have been extensively investigated with a view to providing early and accurate information on long-term outcome and prediction of response to treatment of early breast cancer. Proliferation is a key feature of the progression of tumors and is now widely estimated by the immunohistochemical assessment of the nuclear antigen Ki-67. The expression of Ki-67 correlates with other measurements of proliferation, including S-phase and bromodeoxyuridine uptake. High Ki-67 is a sign of poor prognosis associated with a good chance of clinical response to chemotherapy, but its independent significance is modest and does not merit measurements in most routine clinical scenarios. However, its application as a pharmacodynamic intermediate marker of the effectiveness of medical therapy holds great promise for rapid evaluation of new drugs.</description><subject>Antineoplastic Agents - pharmacokinetics</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - pathology</subject><subject>Cell Proliferation</subject><subject>Female</subject><subject>Gene Expression Profiling</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Ki-67 Antigen - analysis</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Prognosis</subject><subject>Tumors</subject><issn>0732-183X</issn><issn>1527-7755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1LAzEQhoMotlbP3mQv6mm3mWTzsUct9bNSDwreQnY3sanbbk1apP_elC70MLwMPPPCPAhdAs6AYDx8GU2zmCzDImMYjlAfGBGpEIwdoz4WlKQg6VcPnYUwxxhySdkp6gGHgnDM-gjefds4a7xeu3aZvGn_Y3zy6lIuErdMxto32-TeGx3WyUgvK-PP0YnVTTAXXQ7Q58P4Y_SUTqaPz6O7SVrlvFinklqJBa8lkEIXZakpk3lZ1caCKGtJoQAsmaXcEJuDNbwGWljN84oxa-MyQDf73pVvfzcmrNXChco0jV6adhMUl5zGySM43IOVb0PwxqqVdwvttwqw2llS0ZLaWVJYqGgpXlx11ZtyYeoD32mJwHUH6FDpxvr4uQsHThBKJNsV3e65mfue_TlvVFjopom1RM2rllBFpBIECP0HUH96eQ</recordid><startdate>20051001</startdate><enddate>20051001</enddate><creator>URRUTICOECHEA, Ander</creator><creator>SMITH, Ian E</creator><creator>DOWSETT, Mitch</creator><general>American Society of Clinical Oncology</general><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20051001</creationdate><title>Proliferation Marker Ki-67 in Early Breast Cancer</title><author>URRUTICOECHEA, Ander ; SMITH, Ian E ; DOWSETT, Mitch</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c469t-83f8076d8129a9bba3584bcdef17bd83191085f36e2f41fe6d139fa64c55ffd13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Antineoplastic Agents - pharmacokinetics</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - pathology</topic><topic>Cell Proliferation</topic><topic>Female</topic><topic>Gene Expression Profiling</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Ki-67 Antigen - analysis</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Prognosis</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>URRUTICOECHEA, Ander</creatorcontrib><creatorcontrib>SMITH, Ian E</creatorcontrib><creatorcontrib>DOWSETT, Mitch</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>URRUTICOECHEA, Ander</au><au>SMITH, Ian E</au><au>DOWSETT, Mitch</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Proliferation Marker Ki-67 in Early Breast Cancer</atitle><jtitle>Journal of clinical oncology</jtitle><addtitle>J Clin Oncol</addtitle><date>2005-10-01</date><risdate>2005</risdate><volume>23</volume><issue>28</issue><spage>7212</spage><epage>7220</epage><pages>7212-7220</pages><issn>0732-183X</issn><eissn>1527-7755</eissn><abstract>Molecular markers have been extensively investigated with a view to providing early and accurate information on long-term outcome and prediction of response to treatment of early breast cancer. Proliferation is a key feature of the progression of tumors and is now widely estimated by the immunohistochemical assessment of the nuclear antigen Ki-67. The expression of Ki-67 correlates with other measurements of proliferation, including S-phase and bromodeoxyuridine uptake. High Ki-67 is a sign of poor prognosis associated with a good chance of clinical response to chemotherapy, but its independent significance is modest and does not merit measurements in most routine clinical scenarios. However, its application as a pharmacodynamic intermediate marker of the effectiveness of medical therapy holds great promise for rapid evaluation of new drugs.</abstract><cop>Baltimore, MD</cop><pub>American Society of Clinical Oncology</pub><pmid>16192605</pmid><doi>10.1200/JCO.2005.07.501</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0732-183X |
| ispartof | Journal of clinical oncology, 2005-10, Vol.23 (28), p.7212-7220 |
| issn | 0732-183X 1527-7755 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68636864 |
| source | MEDLINE; American Society of Clinical Oncology Online Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Antineoplastic Agents - pharmacokinetics Biological and medical sciences Biomarkers, Tumor - analysis Breast Neoplasms - drug therapy Breast Neoplasms - pathology Cell Proliferation Female Gene Expression Profiling Gynecology. Andrology. Obstetrics Humans Immunohistochemistry Ki-67 Antigen - analysis Mammary gland diseases Medical sciences Prognosis Tumors |
| title | Proliferation Marker Ki-67 in Early Breast Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T07%3A57%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Proliferation%20Marker%20Ki-67%20in%20Early%20Breast%20Cancer&rft.jtitle=Journal%20of%20clinical%20oncology&rft.au=URRUTICOECHEA,%20Ander&rft.date=2005-10-01&rft.volume=23&rft.issue=28&rft.spage=7212&rft.epage=7220&rft.pages=7212-7220&rft.issn=0732-183X&rft.eissn=1527-7755&rft_id=info:doi/10.1200/JCO.2005.07.501&rft_dat=%3Cproquest_cross%3E68636864%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68636864&rft_id=info:pmid/16192605&rfr_iscdi=true |